Rest Of Europe mRNA Synthesis & Manufacturing Market (2024-2029)
The Rest Of Europe mRNA Synthesis & Manufacturing Market was valued at $57.62 Million in 2024 and projected to reach to $65 Million by 2029, representing a compound annual growth rate of 2.4%. Rest Of Europe's mRNA synthesis and manufacturing market is positioned for steady, albeit modest, growth through 2029.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Rest Of Europe mRNA Synthesis & Manufacturing Market Trends and Insights
- Rest Of Europe encompasses a diverse set of healthcare and biotech ecosystems that are gradually adopting mRNA manufacturing capabilities, though at a more measured pace than Western European hubs.
- The region's growth is supported by increasing investment in vaccine development infrastructure and emerging partnerships between local manufacturers and global biopharmaceutical companies seeking to diversify production capacity across Europe. Rest Of Europe faces unique challenges including regulatory harmonization across multiple national frameworks and varying levels of manufacturing infrastructure maturity.
- Despite these headwinds, Rest Of Europe is positioning itself as a secondary manufacturing hub, with several countries establishing dedicated mRNA production facilities to support both domestic and export demand.
- The modest 2.4% CAGR reflects Rest Of Europe's gradual market penetration, balanced against growing recognition of the region's strategic importance in European supply chain resilience through 2029..
Key Market Statistics
- CAGR (2024-2029) 2.4% CAGR
- Market Size, 2024 ~USD 57.62 Million
- Forecast, 2029 ~USD 65 Million
- Country Rest Of Europe
Rest Of Europe mRNA Synthesis & Manufacturing Market Overview
Moderate Growth Trajectory :
Rest Of Europe's mRNA synthesis and manufacturing market is expanding at a CAGR of 2.4%, significantly slower than the global rate of 5.8%, reflecting the region's gradual adoption of advanced biotech infrastructure and manufacturing capabilities.
Market Valuation Growth :
The market is estimated at USD 57.62 million in 2024 and is projected to reach USD 65.0 million by 2029, representing an incremental USD 7.38 million expansion over the five-year forecast period.
Emerging Biotech Ecosystems :
Rest Of Europe encompasses diverse healthcare and biotech ecosystems with varying levels of mRNA manufacturing maturity, creating opportunities for capacity building and technology transfer initiatives across the region.
Measured Adoption Pace :
Unlike Western Europe's rapid advancement, Rest Of Europe is adopting mRNA manufacturing at a more measured pace, driven by regulatory harmonization, investment in R&D infrastructure, and growing pharmaceutical partnerships.
Rest Of Europe mRNA Synthesis & Manufacturing Market Dynamics
- The region's slower expansion compared to global benchmarks reflects ongoing infrastructure development, regulatory framework establishment, and the gradual transition from contract manufacturing dependencies to in-house capabilities.
- Key drivers include increased government support for biotech innovation, rising pharmaceutical investments in emerging markets, and growing demand for personalized medicine solutions. The forecast period will likely see consolidation among regional manufacturers, strategic partnerships with Western European leaders, and targeted investments in production facilities across Central and Eastern European nations.
- Regulatory alignment with EU standards and capacity expansion initiatives will be critical enablers.
- However, competitive pressures from established Western European players and limited venture capital availability may continue to constrain growth velocity, maintaining the region's measured development trajectory..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Analytical And Scientific Instrumentation
- Environmental Testing
- Gas Chromatography
- Polymerase Chain Reaction (PCR)
- Automated Liquid Handling Systems
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Danaher Corporation
- Agilent Technologies, Inc.
- Shimadzu Corporation
- Merck KGaA
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Thermo Fisher Scientific Inc.
- SANOFI
- Merck KGaA
- NOVARTIS
- Pfizer Inc.
Key Takeaways
- Rest Of Europe's mRNA synthesis market is valued at USD 57.62 million in 2024 and will reach USD 65.0 million by 2029 at a 2.4% CAGR.
- Rest Of Europe is emerging as a secondary manufacturing hub with growing investment in mRNA production infrastructure and capacity.
- Rest Of Europe faces regulatory complexity across multiple national frameworks, which moderates growth compared to more established Western European markets.
- Rest Of Europe's strategic importance in European supply chain diversification is driving gradual but steady adoption of mRNA manufacturing technologies.
mRNA Synthesis & Manufacturing Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | MRNA SYNTHESIS & MODIFICATION SERVICES (Service) |
| Forecast Period | 2024-2029 |
| Growth Rate | CAGR of 5.8% from 2024 to 2029 |
| Largest Segment | CONSUMABLES (Product) |
| Market Size Base Year (Billions) | ~USD 2.23 (2024) |
| Revenue Forecast (Billions) | ~USD 2.96 (2029) |
| Segments Covered | Product, Type, Application, End User, Service, Consumables, Transcription Consumables, Purification Consumables, Analysis & Characterization Consumables |
Rest Of Europe mRNA Synthesis & Manufacturing Market Report Segmentation
9 segment dimensions are covered across the global market.
By Product
- Consumables
- Instruments
By Type
- Analysis & Characterization Consumables
- Analysis Kits And Reagents
- Chromatography Filters & Membrane
- Mrna Profiling Kits
- Mrna Synthesis Kits
- Nucleotides
- Other Products
- Other Purification Consumables
- Other Transcription Consumables
- Plasmid Dna/Dna Templates
- Purification Consumables
- Purification Kits & Reagents
- Rna Polymerases
- Transcription Consumables
- Vectors
By Application
- Cell & Gene Therapies
- Other Applications
- Vaccines
By End User
- Academic & Research Institutions
- Cros & Cdmos
- Cros And Cdmos
- Pharmaceutical & Biotechnology Companies
- Small-Scale Cros & Cdmos
By Service
- Manufacturing & Scale-Up Services
- Mrna Analysis & Characterization Services
- Mrna Purification Services
- Mrna Synthesis & Modification Services
By Consumables
- Analysis & Characterization Consumables
- Purification Consumables
- Transcription Consumables
By Transcription Consumables
- Mrna Profiling Kits
- Mrna Synthesis Kits
- Nucleotides
- Other Transcription Consumables
- Plasmid Dna/Dna Templates
- Rna Polymerases
- Vectors
By Purification Consumables
- Chromatography Filters & Membranes
- Other Purification Consumables
- Purification Kits & Reagents
- Purification Kits And Reagents
By Analysis & Characterization Consumables
- Analysis Kits & Reagents
- Analysis Kits And Reagents
- Other Analysis & Characterization Consumables
Target Audience
- Pharmaceutical Manufacturers : Evaluate Rest Of Europe as a manufacturing hub or partnership destination for mRNA-based therapeutics, assessing regional capacity, regulatory pathways, and cost-effectiveness compared to Western European alternatives.
- Contract Manufacturing Organizations (CMOs) : Identify expansion opportunities in Rest Of Europe's underserved mRNA manufacturing market, where demand for contract services is rising but supply remains limited, enabling service differentiation and market penetration.
- Biotech Investors & Venture Capitalists : Assess investment potential in Rest Of Europe's emerging mRNA ecosystem, identifying promising startups, infrastructure projects, and technology platforms positioned to capture regional market growth through 2029.
- Government & Policy Bodies : Leverage market data to inform biotech policy development, funding allocation, and infrastructure investment decisions aimed at strengthening Rest Of Europe's mRNA manufacturing capabilities and competitiveness.
- Equipment & Technology Suppliers : Understand Rest Of Europe's specific demand for mRNA synthesis equipment, analytical tools, and manufacturing technologies, enabling targeted product development and sales strategies for this growing regional market segment.
Reasons to Buy this Report
- Regional Market Differentiation : Gain specific insights into Rest Of Europe's unique mRNA market dynamics, distinct from Western Europe, enabling targeted market entry strategies and localized business development approaches for this emerging biotech region.
- Growth Opportunity Identification : Identify high-potential markets within Rest Of Europe where mRNA manufacturing infrastructure is underdeveloped, presenting first-mover advantages for investors, manufacturers, and technology providers seeking expansion opportunities.
- Competitive Landscape Analysis : Understand regional competitive positioning, manufacturing capacity gaps, and partnership opportunities specific to Rest Of Europe, enabling informed decisions on market share capture and strategic alliances.
- Investment Decision Support : Access quantified market projections (USD 57.62M to USD 65M) and CAGR data (2.4%) to support capital allocation decisions, feasibility studies, and ROI forecasting for Rest Of Europe-focused initiatives.
- Regulatory & Infrastructure Insights : Understand the region's regulatory environment, infrastructure maturity levels, and government support mechanisms that influence mRNA manufacturing adoption, critical for compliance and operational planning.
Frequently asked questions
What is the current market size of mRNA synthesis and manufacturing in Rest Of Europe?
Rest Of Europe's mRNA synthesis and manufacturing market is estimated at USD 57.62 million in 2024.
What is the projected market size for Rest Of Europe by 2029?
Rest Of Europe's mRNA synthesis and manufacturing market is forecast to reach USD 65.0 million by 2029.
What is the CAGR for Rest Of Europe's mRNA synthesis market?
Rest Of Europe's mRNA synthesis and manufacturing market is expected to grow at a CAGR of 2.4% from 2024 to 2029.
Why is Rest Of Europe's growth rate lower than the global average?
Rest Of Europe's 2.4% CAGR reflects the region's gradual infrastructure development, regulatory complexity across multiple national frameworks, and its positioning as a secondary manufacturing hub compared to more established Western European markets.
What factors are driving growth in Rest Of Europe's mRNA market?
Growth in Rest Of Europe is driven by increasing vaccine development investments, emerging partnerships with global biopharmaceutical companies, and the region's strategic importance in diversifying European mRNA manufacturing capacity.
RESEARCH METHODOLOGY
The study involved major activities in estimating the current market size for the mRNA synthesis and manufacturing market. Exhaustive secondary research was done to collect information on the mRNA synthesis and manufacturing industry. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain using primary research. Different approaches, such as market share analysis, MnM repository analysis, were employed to estimate the total market size. After that, the market breakup and data triangulation procedures were used to estimate the market size of the segments and subsegments of the mRNA synthesis and manufacturing market.
Secondary Research
The market for the companies offering mRNA synthesis and manufacturing solutions is arrived at by secondary data available through paid and unpaid sources, analyzing the product & service portfolios of the major companies in the ecosystem, and rating the companies by their performance and quality. Various sources were referred to in the secondary research process to identify and collect information for this study. The secondary sources include annual reports, press releases, investor presentations of companies, white papers, journals, certified publications, and articles from recognized authors, directories, and databases. In the secondary research process, various secondary sources were referred to for identifying and collecting information related to the study. Secondary sources included annual reports, press releases, and investor presentations of blockchain vendors, forums, certified publications, and whitepapers. The secondary research was used to obtain critical information on the industry’s value chain, the total pool of key players, market classification, and segmentation from the market and product-oriented perspectives.
Primary Research
Extensive primary research was conducted after acquiring basic knowledge about the global mRNA synthesis and manufacturing market scenario. Several primary interviews were conducted with market experts from both the demand side (such as personnel from the pharmaceutical & biopharmaceutical industry) and the supply side (such as C-level and D-level executives, product managers, marketing and sales managers of key manufacturers, distributors, as well as channels) across five major regions, namely, North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. Approximately 80% and 20% of primary interviews were conducted with supply-side and demand-side participants, respectively. This primary data was collected through questionnaires, e-mails, and online, personal, and telephonic interviews.
The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
Top-down approache was used to estimate and validate the total size of the mRNA synthesis and manufacturing market. These methods include market share analysis, MnM repository analysis were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
- The key players in the industry and market have been identified through extensive secondary research.
- The revenues generated from the mRNA synthesis and manufacturing market business of leading players have been determined through primary and secondary research.
- All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.
After arriving at the overall market size from the market size estimation process, the total market was split into several segments and subsegments.
Data Triangulation
After arriving at the market size from the market size estimation process explained above, the total market was divided into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable.
Market Definition
mRNA synthesis and manufacturing refers to the process of producing messenger RNA (mRNA) through in vitro transcription, followed by various purification, and characterization steps to create high-quality mRNA products suitable for research, therapeutic, or vaccine applications. The mRNA synthesis and manufacturing market encompasses the development, production, and commercialization of messenger RNA (mRNA) products, including their synthesis via in vitro transcription, large-scale manufacturing, and formulation. This market serves various applications such as vaccines, therapeutic treatments, and potentially other areas like protein replacement. It involves specialized technologies and equipment, adherence to regulatory standards, and a global supply chain network.
The study provides an in-depth analysis of the mRNA synthesis and manufacturing market based on contemporary market trends and developments, and its potential growth from 2024 to 2029. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key mRNA synthesis and manufacturing product and service providers.
Stakeholders
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
- Contract Development and Manufacturing Organizations (CDMOs)
- Raw Material Suppliers
- Market Research and Consulting Firms
- Regulatory Agencies
- Venture Capitalists
- Government Organizations
- Industry Associations and Professional Societies
Report Objectives
- To define, describe, and forecast the mRNA synthesis and manufacturing market based on product, service, application, and region
- To define, describe, and forecast the mRNA synthesis and manufacturing market based on product by end user and service by end user
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the mRNA synthesis and manufacturing market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To profile the key players in the global mRNA synthesis and manufacturing market and comprehensively analyze their products and services portfolios, market positions, and core competencies.
- To track and analyze competitive developments such as product/service launches, expansions, agreements, and collaborations in the mRNA synthesis and manufacturing market
- To benchmark players within the mRNA synthesis and manufacturing market using the Company Evaluation Matrix framework, which analyzes market players based on various parameters within the broad categories of business and service strategy
Get the Full mRNA Synthesis & Manufacturing Market Report
Full forecast, segment splits, and company analysis for all mRNA Synthesis & Manufacturing Market.
- Canada mRNA Synthesis & Manufacturing Market
- US mRNA Synthesis & Manufacturing Market
- Germany mRNA Synthesis & Manufacturing Market
- UK mRNA Synthesis & Manufacturing Market
- France mRNA Synthesis & Manufacturing Market
- Switzerland mRNA Synthesis & Manufacturing Market
- Italy mRNA Synthesis & Manufacturing Market
- Spain mRNA Synthesis & Manufacturing Market
- China mRNA Synthesis & Manufacturing Market
- Japan mRNA Synthesis & Manufacturing Market
- India mRNA Synthesis & Manufacturing Market
- South Korea mRNA Synthesis & Manufacturing Market
- Brazil mRNA Synthesis & Manufacturing Market
- Rest Of Asia Pacific mRNA Synthesis & Manufacturing Market
- Rest Of Latin America mRNA Synthesis & Manufacturing Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
